S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
IPSC · Century Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Century Therapeutics Inc (IPSC)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$1.61
-0.02
(-1.23%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$1.61
$1.52
$1.65
52-WEEK RANGE
$1.61
$0.43
$3.04
What's happening
- IPSC is down 1.23% today, trading at $1.61. — Live quote
- Volume today (85,950) is well below its 3-month average of 976,490. (Finnhub fundamentals)
- Reports earnings on 2026-11-11 (before market open), 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.11 actual vs. $-0.12 estimated (+5.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 8
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-09-01 (12 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
IPSC
+37.72%
vs S&P 500
+25.79%
1-YEAR RETURN
IPSC
+146.05%
vs S&P 500
+130.52%
6-MONTH RETURN
IPSC
-42.19%
3-MONTH RETURN
IPSC
-39.11%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.11
Est. $-0.12
BEAT +5.0%
2026-04-26 (Q1 2026)
$-0.11
Est. $-0.16
BEAT +31.8%
2026-01-26 (Q4 2025)
$-0.22
Est. $-0.29
BEAT +23.9%
2025-10-26 (Q3 2025)
$-0.32
Est. $-0.34
BEAT +7.1%
Valuation Measures & Ratios
Enterprise Value4$198.4M
Forward P/E5—
PEG Ratio6-0.01
Price / Sales (TTM1)2.16
Price / Book71.90
EV4 / Revenue1.73
EV4 / EBITDA—
Profit Margin-18.92%
Operating Margin-28.63%
Return on Equity (ROE8)-52.76%
Return on Assets (ROA9)-40.59%
Avg Volume (3M)976,490
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $496.9M | $444.7M | $42.9M | $47.7M | $41.2M |
| P/E | -4.03 | -36.91 | -1.98 | -2.59 | -2.95 |
| Price/Sales | — | — | — | — | 0.37 |
| Price/Book | 2.14 | 1.68 | 0.24 | 0.23 | 0.17 |
| EV/Revenue | — | — | — | — | -0.10 |
| ROE | -53.01% | -4.55% | -12.26% | -8.77% | -5.80% |
| ROA | -42.91% | -3.69% | -8.84% | -6.47% | -4.42% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short29,218,775
Change from Prior Settlement-0.46%
% of Float—
Days to Cover (Short Ratio)50.91
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +146.0%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -18.9%. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-02; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on IPSC
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $109.2M | $791.0K | $771.0K | $855.0K |
| Operating income | -$36.5M | -$23.7M | -$36.1M | -$34.7M | $74.2M | -$34.8M | -$34.8M | -$31.3M |
| Net income | -$34.5M | -$21.6M | -$34.4M | -$32.5M | $76.6M | -$31.2M | -$31.2M | -$28.1M |
| EPS (diluted) | $-0.17 | $-0.11 | $-0.40 | $-0.38 | $0.89 | $-0.37 | $-0.38 | $-0.45 |
| EPS (basic) | $-0.17 | $-0.11 | $-0.40 | $-0.38 | $0.89 | $-0.37 | $-0.38 | $-0.45 |
| Operating margin | — | — | — | — | $68 | -$4.4K | -$4.5K | -$3.7K |
| Net margin | — | — | — | — | $70 | -$3.9K | -$4.0K | -$3.3K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $287.0M | $326.6M | $223.7M | $244.7M | $284.7M | $315.6M | $353.2M | $388.6M |
| Total liabilities | $54.7M | $61.8M | $64.8M | $68.4M | $74.8M | $75.2M | $191.9M | $192.9M |
| Stockholders' equity | $232.3M | $264.7M | $158.9M | $176.3M | $209.9M | $240.4M | $161.4M | $195.7M |
| Total current assets | $124.8M | $139.0M | $120.8M | $137.7M | $160.2M | $169.6M | $194.1M | $206.0M |
| Total current liabilities | $15.1M | $13.6M | $20.2M | $22.0M | $14.9M | $14.5M | $129.8M | $19.8M |
| Cash & equivalents | $49.6M | $51.0M | $61.9M | $55.5M | $56.9M | $51.9M | $58.4M | $52.6M |
| Marketable securities (current) | $70.1M | $83.8M | $55.3M | $77.2M | $99.0M | $113.3M | $130.9M | $145.5M |
| Other current assets | — | — | — | — | — | — | — | — |
| Marketable securities (non-current) | $77.5M | $82.2M | — | — | $2.7M | $20.7M | $30.8M | $46.6M |
| Property, plant & equipment | $34.5M | $47.6M | $50.0M | $53.7M | $56.6M | $59.5M | $62.1M | $65.3M |
| Goodwill | — | — | — | — | — | — | — | $4.7M |
| Intangible assets | $34.2M | $34.2M | $34.2M | $34.2M | $34.2M | $34.2M | $34.2M | $33.8M |
| Accounts payable | $4.8M | $3.1M | $4.8M | $2.6M | $3.2M | $3.6M | $3.1M | $2.6M |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | — | — | — | — | — | — | $109.2M | $3.6M |
| Other current liabilities | — | — | — | $1.0M | $49.0K | $111.0K | $75.0K | $84.0K |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $666.0K | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $18.0K | $18.0K | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K |
| Retained earnings | -$848.1M | -$813.6M | -$791.9M | -$772.7M | -$738.3M | -$705.8M | -$782.3M | -$746.3M |
| Accumulated other comprehensive income (loss) | -$694.0K | -$585.0K | $30.0K | $64.0K | $83.0K | $305.0K | $324.0K | $758.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$19.8M | -$25.3M | -$16.1M | -$25.6M | -$27.6M | -$34.6M | -$24.2M | -$28.3M |
| Investing cash flow | $17.8M | -$112.6M | $22.4M | $24.7M | $32.5M | $27.9M | $30.6M | $39.2M |
| Financing cash flow | $311.0K | $126.6M | $53.0K | $0 | $0 | $120.0K | -$602.0K | $273.0K |
| Free cash flow | -$20.5M | -$25.8M | -$15.9M | -$25.8M | -$27.9M | -$35.1M | -$23.6M | — |
| Capital expenditures | $694.0K | $584.0K | -$139.0K | $195.0K | $317.0K | $475.0K | -$650.0K | — |
| Share-based compensation | $1.9M | $1.4M | $1.3M | $892.0K | $2.2M | $2.4M | $2.7M | $3.3M |
| Deferred income taxes | — | — | -$73.0K | — | — | — | $870.0K | — |
| Change in accounts payable | $1.7M | -$1.6M | $2.2M | -$591.0K | -$365.0K | $361.0K | $477.0K | -$757.0K |
| Purchases of investments | $16.0M | $140.7M | $15.6M | $11.0M | $9.7M | $14.9M | $17.4M | $13.2M |
| Sales/maturities of investments | $34.4M | $28.7M | $37.8M | $35.9M | $42.5M | $43.3M | $48.2M | $51.6M |
| Debt repaid | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $109.2M | $6.6M | $2.2M | $5.2M | — |
| Operating income | -$17.3M | -$138.1M | -$146.5M | -$133.8M | -$94.9M |
| Net income | -$9.6M | -$126.6M | -$136.7M | -$130.9M | -$95.8M |
| EPS (diluted) | $-0.14 | $-1.61 | $-2.30 | $-2.96 | $-2.96 |
| EPS (basic) | $-0.14 | $-1.61 | $-2.30 | $-2.27 | $-2.96 |
| Operating margin | -$16 | -$2.1K | -$6.6K | -$2.6K | — |
| Net margin | -$9 | -$1.9K | -$6.1K | -$2.5K | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $223.7M | $353.2M | $360.7M | $486.5M | $437.4M |
| Total liabilities | $64.8M | $191.9M | $175.9M | $183.8M | $41.1M |
| Stockholders' equity | $158.9M | $161.4M | $184.8M | $302.7M | $396.2M |
| Total current assets | $120.8M | $194.1M | $177.0M | $319.7M | $228.2M |
| Total current liabilities | $20.2M | $129.8M | $17.8M | $29.8M | $15.7M |
| Cash & equivalents | $61.9M | $58.4M | $47.3M | $84.3M | $56.4M |
| Marketable securities (current) | $55.3M | $130.9M | $125.4M | $231.2M | $166.4M |
| Other current assets | — | — | $1.6M | — | $250.0K |
| Marketable securities (non-current) | — | $30.8M | $89.1M | $51.9M | $135.9M |
| Property, plant & equipment | $50.0M | $62.1M | $71.7M | $82.8M | $58.0M |
| Intangible assets | $34.2M | $34.2M | — | — | — |
| Accounts payable | $4.8M | $3.1M | $2.7M | $5.5M | $7.6M |
| Deferred revenue (current) | — | $109.2M | $4.4M | $7.2M | — |
| Other current liabilities | — | $75.0K | $28.0K | $236.0K | — |
| Long-term debt | — | — | — | $10.4M | $10.4M |
| Common stock & paid-in capital | $9.0K | $9.0K | $6.0K | $6.0K | $5.0K |
| Retained earnings | -$791.9M | -$782.3M | -$655.8M | -$519.1M | -$388.2M |
| Accumulated other comprehensive income (loss) | $30.0K | $324.0K | $108.0K | -$2.5M | -$650.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$103.9M | -$110.1M | -$88.3M | $14.1M | -$89.0M |
| Investing cash flow | $107.5M | $47.5M | $61.1M | -$13.1M | -$298.3M |
| Financing cash flow | $173.0K | $74.6M | -$9.7M | $27.2M | $417.8M |
| Free cash flow | -$104.7M | -$110.3M | -$102.1M | -$16.6M | -$134.0M |
| Capital expenditures | $848.0K | $154.0K | $13.7M | $30.6M | $45.0M |
| Share-based compensation | $6.8M | $12.7M | $14.6M | $10.7M | $4.7M |
| Deferred income taxes | -$73.0K | $870.0K | -$3.0K | $5.0K | — |
| Change in accounts payable | $1.6M | -$1.5M | -$2.4M | -$4.8M | -$1.8M |
| Purchases of investments | $51.2M | $119.5M | $209.0M | $254.0M | $330.0M |
| Sales/maturities of investments | $159.5M | $176.8M | $283.9M | $271.5M | $76.7M |
| Debt repaid | — | — | $10.2M | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding IPSC as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-04-01 to 2026-09-14
Recent transactions
- Insiders have net sold 10,583 shares over the last 182 days, across 0 purchases and 10 sales.
- Most recent: Russotti Gregory (See Remarks) — Open market sale of 2,587 shares on 2026-09-14.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)10,583 sh(10 txns)
Net Shares-10,583
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Russotti Gregory | See Remarks | Open market sale | 2026-09-14 | 2,587 |
| Carr Douglas | SVP Finance & Operations | Open market sale | 2026-09-14 | 1,658 |
| Pfeiffenberger Brent | President and CEO | Tax withholding | 2026-09-11 | 13,850 |
| Cowan Chad | Chief Scientific Officer | Tax withholding | 2026-06-11 | 358 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-14 | Russotti Gregory | See Remarks | Open market sale | 2,587 | $1.93 |
| 2026-09-14 | Carr Douglas | SVP Finance & Operations | Open market sale | 1,658 | $1.93 |
| 2026-09-11 | Pfeiffenberger Brent | President and CEO | Tax withholding | 13,850 | $1.94 |
| 2026-09-08 | Russotti Gregory | See Remarks | Open market sale | 534 | $2.05 |
| 2026-09-08 | Carr Douglas | SVP Finance & Operations | Open market sale | 254 | $2.05 |
| 2026-09-04 | Pfeiffenberger Brent | President and CEO | Tax withholding | 463 | $2.11 |
| 2026-08-14 | Pfeiffenberger Brent | President and CEO | Tax withholding | 31,172 | $1.92 |
| 2026-08-03 | Carr Douglas | SVP Finance & Operations | Open market sale | 275 | $1.98 |
| 2026-06-12 | Russotti Gregory | See Remarks | Open market sale | 2,584 | $2.23 |
| 2026-06-12 | Carr Douglas | SVP Finance & Operations | Open market sale | 1,654 | $2.23 |
| 2026-06-11 | Pfeiffenberger Brent | President and CEO | Tax withholding | 13,849 | $2.24 |
| 2026-06-11 | Cowan Chad | Chief Scientific Officer | Tax withholding | 358 | $2.24 |
| 2026-06-08 | Russotti Gregory | See Remarks | Open market sale | 524 | $2.11 |
| 2026-06-08 | Carr Douglas | SVP Finance & Operations | Open market sale | 249 | $2.11 |
| 2026-06-05 | Pfeiffenberger Brent | President and CEO | Tax withholding | 463 | $2.13 |
| 2026-05-15 | Pfeiffenberger Brent | President and CEO | Tax withholding | 31,172 | $2.34 |
| 2026-05-04 | Carr Douglas | SVP Finance & Operations | Open market sale | 264 | $2.34 |
| 2026-04-01 | Cowan Chad | Chief Scientific Officer | Tax withholding | 1,365 | $2.19 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 01:25 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-02 | 8-K | 2026-10-02 | View on SEC.gov → |
| 2026-09-15 | 4 | 2026-09-14 | View on SEC.gov → |
| 2026-09-15 | 4 | 2026-09-14 | View on SEC.gov → |
| 2026-09-15 | 4 | 2026-09-11 | View on SEC.gov → |
| 2026-09-10 | 4 | 2026-09-09 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-08 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-08 | View on SEC.gov → |
| 2026-09-09 | 8-K | 2026-09-09 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-14 | View on SEC.gov → |
| 2026-08-12 | 8-K | 2026-08-12 | View on SEC.gov → |
| 2026-08-12 | 10-Q | 2026-06-30 | View on SEC.gov → |
Recent news
Headlines about IPSC (Century Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Century Therapeutics (IPSC) Slips 8.67% to $1.37, Pressing Toward Key Support - Risk Parity Rebalance
https://www.siam.in/ · 2026-10-16 -
Century Therapeutics presents CNTY-813 data: what it means for Century Therapeutics stock - ad-hoc-news.de
ad-hoc-news.de · 2026-10-16 -
IPSC Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 4.71% - Earnings Cycle Report
https://www.siam.in/ · 2026-10-15 -
Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London
Yahoo Finance · 2026-10-14 -
Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
Yahoo Finance · 2026-10-02 -
Century Therapeutics: Competitors May Be Quietly De-Risking Its Biggest Bet
Seeking Alpha · 2026-09-30 -
Century Therapeutics Appoints Joseph Truitt to Board of Directors
Yahoo Finance · 2026-09-09 -
Century Therapeutics GAAP EPS of -$0.17 misses by $0.05
Seeking Alpha · 2026-08-12
No headlines in this category right now — try “All”.